We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The Netherlands-based biotech Citryll and contract development and manufacturing organization (CDMO) Lonza have entered a partnership to develop and manufacture Citryll’s tACPA therapeutic antibody CIT-013.